NeuroVive Asia signs deal with Sanofi for CicloMulsion in South Korea

Swedish mitochondrial medicines firm NeuroVive Pharmaceutical (Nasdaq OMX AB: NVP) says that its subsidiary, NeuroVive Pharmaceutical Asia, has signed a collaboration agreement with the local affiliate of French pharma major Sanofi (Euronext: SAN) for the development and commercialization of CicloMulsion (cyclosporine) in South Korea.

Under the deal, NeuroVive Asia will receive an undisclosed upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. CicloMulsion is being developed for the treatment of reperfusion injury in cardiovascular disease. The agreement encompasses the registration, launch, promotion and sale of CicloMulsion in South Korea.

“The collaboration with Sanofi will enable us to broaden the commercialization of CicloMulsion for the treatment of cardiovascular disease. South Korea is an important market in Asia and this collaboration with Sanofi is further confirmation of CicloMulsion’s clinical and commercial potential. I look forward to a long and productive partnership with Sanofi, with the aim of launching CicloMulsion for the treatment of acute cardiovascular indications on the South Korean market,” commented Mikael Brönnegård, NeuroVive’s chief executive.